Montelukast in dengue fever
Phase 3
- Conditions
- Health Condition 1: B978- Other viral agents as the cause ofdiseases classified elsewhere
- Registration Number
- CTRI/2023/11/059752
- Lead Sponsor
- Indian Council Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age more than 18 years
2. Confirmed dengue fever (NS 1 positive)
Exclusion Criteria
1. Presence of warning sign or features of severe dengue
2. Patients with concurrent other cause of fever
3. Known leukemia/bleeding disorder like ITP
4. Patients taking steroids
5. Already on montelukast for other indication
6. Pregnancy/lactation
7. Unable to take medicine by mouth
8. Refusal to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of warning signs and severe disease in patients with dengue fever who receive Montelukast compared to those who receive a placebo.Timepoint: 5 days
- Secondary Outcome Measures
Name Time Method 1.Duration of fever in patients with dengue fever who receive Montelukast compared to those who receive a placebo. <br/ ><br>2.Hospitalization rates in patients with dengue fever who receive Montelukast compared to those who receive a placebo. <br/ ><br>3.Mortality rates in patients with dengue fever who receive Montelukast compared to those who receive a placebo. <br/ ><br>4.Adverse events related to Montelukast treatment in patients with dengue fever. <br/ ><br>Timepoint: 3,6,12,24,36 months